By Amber Glende – If you work in life sciences, whether in pharma, diagnostics, or vaccines, Federally Qualified Health Centers might not be on your radar. Many manufacturers focus their commercial strategies on large health systems, private practices, and specialty networks, leaving FQHCs largely untapped.
Read More
By Tom Dorsett – As of April 2023, the FDA has approved the use of 40 “biosimilars”, which are a less expensive version of an advanced “biologic” medication. The rise of biosimilars is a major source of excitement as a way to control rising drug costs. But is the fervor warranted?
By Kayla Matthews – A recent Cornell University study was the first of its kind to examine the prescribing behavior before and after receiving complimentary food. The institution’s goal was to see if these in-kind payments directly affect whether doctors prescribe certain drugs to their patients.
By Sarianne Gruber – How pharma rethinks its marketing will be on par with how healthcare will embrace value-based care. Succeeding in value-based care may indeed be the impetus for pharma to embrace new “technologies” to help patients better adhere to medication regimens.
By Sarianne Gruber – Having been successful for decades maintaining a traditional a product-driven model, pharmaceutical companies are feeling their way toward a new business model: patient-centricity.